Conference Board of Directors

  • Frederick Beddingfield III, MD, PhD, FAAD
  • Chief Executive Officer , Sienna Biopharmaceuticals, Inc.
  • Associate Clinical Professor , UCLA Dermatology

Frederick Beddingfield III, MD, PhD is CEO of Sienna Biopharmaceuticals, Inc, a company focused on developing breakthrough products in aesthetics and dermatology. He is also a board-certified dermatologist and dermatologic surgeon. Dr Beddingfield served as Chief Medical Officer of Kythera Biopharmaceuticals from March, 2013 until it was acquired by Allergan in October, 2015.

Prior to his appointment at Kythera, he held the role of Vice President and Therapeutic Area Head, Dermatology and Aesthetics at Allergan, Inc. Dr. Beddingfield led the development of premier products in the dermatology and aesthetics industry, including KYBELLA®, BOTOX® Cosmetic, JUVEDERM XC®, VOLUMA XC®, and LATISSE®, all market-leading aesthetic treatments in their respective categories. During his tenure at Allergan, Dr. Beddingfield also led programs in acne, rosacea, scarring, hyperhidrosis, and hair loss.

Dr. Beddingfield earned an MD Degree with Honors from the University of North Carolina and a PhD in Policy Analysis from RAND Graduate School of Policy Studies.

  • Albert Cha, MD, PhD
  • Managing Partner , Vivo Capital

Albert Cha, M.D., Ph.D. is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. He currently serves on the boards of Aclaris Therapeutics (NASDAQ: ACRS), Ascendis Pharma A/S (NASDAQ: ASND), ProNAi Therapeutics (NASDAQ: DNAI), Carbylan Therapeutics (NASDAQ: CBYL), AirXpanders (ASX: AXP), and several private companies. He was an investor in Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and Prestwick Pharmaceuticals (acquired by Biovail). Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG).

Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer. Albert received his B.S. and M.S. in Electrical Engineering from Stanford University. He subsequently completed the Medical Scientist Training Program at UCLA School of Medicine, where he received his M.D. and Ph.D. in Neuroscience.

  • John Doux, MD, MBA, FAAD
  • Investor , Palo Alto Investors

John Doux, MD obtained a B.S. with distinction and an MD from Stanford University, where he was a Howard Hughes Medical Institute Fellow performing research in the laboratory of Dr. David Woodley. After an internship at Brigham and Women's Hospital in Boston, he returned to Stanford to complete his residency training in dermatology. He also completed an MBA at the Wharton School of Business where he was a Palmer Scholar. He is board certified in dermatology and maintains an active clinical practice. Since 2004 he has also served as an analyst at Palo Alto Investors, an investment fund specializing in healthcare with $1B in assets under management.

  • William Ju, MD, FAAD
  • President , Advancing Innovation in Dermatology, Inc.

William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad spectrum of product development functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™. Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University. Dr. Ju is a co-founder of Zoomi, Inc., is currently a member of the board of directors for Zoomi, Inc. and for Brickell Biotech, Inc., is a trustee of the Morristown Medical Center Foundation, and serves on the Advisory Council for the Keller Center of entrepreneurship at Princeton University.

  • Seth Orlow, MD, PhD, FAAD
  • Senior Advisor , Pharus Advisors
  • Professor & Chair of Dermatology , NYU School of Medicine

Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.

  • Dr. Neal Walker, MBA
  • Founder & Chief Executive Officer , Aclaris Therapeutics

Dr. Neal Walker is the President & Chief Executive Officer at Aclaris. He is a board certified dermatologist and serial entrepreneur with over 18 years of experience in the biopharmaceutical industry. Prior to founding Aclaris, he was co-founder, President and CEO of Vicept Therapeutics (acquired by Allergan). Dr. Walker has co-founded and led a number of life science companies: Octagon Research Solutions, a software and services provider to biopharmaceutical companies (acquired by Accenture); Trigenesis Therapeutics, a specialty dermatology company where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories); Cutix Inc., a commercial dermatology company that markets PreSun®, a sunscreen brand acquired from Bristol-Myers Squibb. He began his pharmaceutical industry career at Johnson and Johnson. Dr. Walker currently serves as Vice Chairman of Alexar Therapeutics, Inc. (co-founder) and Director on the Board of Sebacia, Inc. He previously served on the Board of Directors for Octagon. He is also on the Advisory Board of Flexible Medical Systems. Dr. Walker received his MBA from The Wharton School, University of Pennsylvania.

Conference Advisory Board

  • Michael Brinkman
  • Managing Director , Global Healthcare Investment Banking Group, Jefferies

Michael Brinkman is a Managing Director in the Global Healthcare Investment Banking Group at Jefferies. He focuses on U.S. Biotechnology and Specialty Pharmaceutical companies. Mr. Brinkman has been one of the most active bankers in the Biotechnology industry during his 22-year investment banking career. Prior to joining Jefferies, he was a Managing Director at Piper Jaffray for two years, and head of biotechnology investment banking at CIBC World Markets where he spent 14 years. Before that Mr. Brinkman worked as an actuary in life and health insurance companies in the U.S. and South Africa. He graduated magna cum laude with a BS degree from the University of the Witwatersrand in South Africa and his Fellowship from the Faculty of Actuaries in Edinburgh, Scotland. Michael’s recent Dermatology clients includes, Aclaris, Anacor and Foamix.

  • Andrea H. Epperly, PhD
  • Head of Business Development & Licensing , Stiefel, a GSK company

Andrea Epperly, PhD, is the Head of Business Development and Licensing at Stiefel, a GSK company, a specialty dermatology division of GlaxoSmithKline (GSK). She is responsible for overseeing the development and delivery of the global business development strategy to continue building a strong pipeline of new and differentiated dermatological medicines. Prior to this, Andrea was a member of GSK’s Worldwide Business Development Team where she was responsible for establishing and executing an out-licensing program for R&D and for closing the spin-out of Convergence Pharmaceuticals. She has over 18 years of experience as a leader of discovery and early development projects within oncology, metabolic diseases, and dermatology. She won multiple awards during her time as a Research Investigator in oncology drug discovery for her Drug Metabolism and Pharmacokinetic work on the currently approved medicine Votrient. Andrea has authored more than 30 original peer-reviewed journal articles and abstracts. She earned her Bachelor and Doctor of Philosophy degrees in Chemistry from Virginia Tech.

  • Peter Nicholson, MBA
  • Vice President, Business Development & Strategy , Nestle Skin Health

Peter Nicholson has worked in the biopharmaceutical and medical device industries for over 25 years. He is responsible for the worldwide strategy and business development functions at Galderma S.A., the dermatology-focused operating company of Nestlé Skin Health, which he joined in 2007. Previously he was Vice President, Corporate Development for Mentor Corporation where he successfully divested the company’s urology business and refocused its strategy on the aesthetic business, which ultimately led to its acquisition by Johnson & Johnson. He served in a similar role at Inamed where he refined the company’s strategy and successfully executed a number of business development agreements and revitalized the company’s international presence prior to its acquisition by Allergan.

Nicholson worked at Amgen for 6 years in roles of increasing responsibility in product development and product licensing and was responsible for starting and managing the company’s venture program. He worked at two small medical device companies, Telios and Advanced Tissues Sciences, where he was a team-member focused on developing products addressing unmet needs for wound healing and burns. He pursued research at Triton Biosciences and Allergenetics, where he was focused on identifying, isolating, and characterizing new growth factors.

Mr. Nicholson received a Master of Business Administration degree from the University of California at Los Angeles where he won the 19th annual Knapp New Ventures Competition. He was a co-founder and Chief Executive Officer of Blue Heron Biotechnology, a genomics company that he grew from 2 to 33 employees and a successful commercial launch. He has a Bachelor of Arts degree in biochemistry with an emphasis in immunology from the University of California at Berkeley, where he did post-graduate research in the laboratory of Dr. Robert I. Mishell.

  • Kevin Sheridan, MBA
  • Managing Director , Global Healthcare Investment Banking Group, Jefferies

Kevin Sheridan is a Managing Director in the Global Healthcare Investment Banking Group at Jefferies, responsible for advising large-cap biopharmaceutical companies in the United States, Europe, and Japan. Prior to joining Jefferies, Mr. Sheridan spent 11 years at UBS, where he advised biotechnology and pharmaceutical companies in the United States. Prior to joining UBS, Mr. Sheridan was employed as a Management Consultant in the Healthcare industry. Mr. Sheridan received his MBA from Columbia Business School and received his BA from Rutgers University.

  • Thorsten Thormann, PhD, MSc
  • Senior Vice President, New Product Discovery , LEO Pharma

Thorsten was appointed Senior Vice President of New Product Discovery, a business unit with more than 200 dedicated scientists and specialists at LEO Pharma in January 2013. In this role, the priorities for Thorsten Thormann have been to continue the building of a strong Research & Development project pipeline at LEO Pharma.

Prior to this, Thorsten held a double role of Director of Biological Research and Director of Pharmaceutical Technologies, respectively. Here he was responsible for disease specific experimental platforms linking biochemistry and exploratory clinical testing as well as refocusing the early formulation and CMC to build a platform for product improvements based on usability and user experience. Thorsten has also held the position as Head of Department, Molecular Biomedicine and Head of Section for Product Reprofiling.

Throughout these positions, Thorsten has gained insights into the importance of having strong ideation processes to create confidences in new targets and concepts as well as establishing high value of life cycle management and product improvements to meet real patient needs.

Thorsten Thormann has a Master of Science in Chemistry from University of Roskilde and a Doctor of Philosophy degree in Protein Biology from University of Copenhagen.

  • Lee T. Zane, MD, FAAD
  • Senior Vice President and Chief Medical Officer , Anacor Pharmaceuticals

Lee T. Zane, MD, is a board-certified dermatologist and Anacor’s Senior Vice President and Chief Medical Officer. He had served as Anacor's Vice President of Clinical Development from August 2008 to October 2013 and its Medical Director since January 2008. From 2003 to 2007, Dr. Zane served as Assistant Professor of Clinical Dermatology at the University of California, San Francisco (UCSF), Department of Dermatology, where he was the Director of the Mt. Zion Dermatology Clinical Research Unit and the Director of the Acne Specialty Practice.

Dr. Zane received his Bachelor of Arts (BA) degree from Colgate University and his Doctor of Medicine (MD) degree from Stanford University. He completed his Dermatology residency training at UCSF, where he also earned a Master of Advanced Studies (MAS) in Clinical Research and maintains a faculty position as Assistant Clinical Professor of Dermatology and Epidemiology & Biostatistics.

Advancing Innovation in Dermatology, Inc. is a registered IRS 501(c)(3) organization designated as a public charity in the United States.